c-Met/VEGFR-2 dual kinase inhibitors (Ascepion)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namec-Met/VEGFR-2 dual kinase inhibitors (Ascepion)
Drug Alias NameASP-08001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptorVascular endothelial growth factor receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesAscepion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAscepion Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A